Course Information

Release date: May 5, 2025
Expiration date: May 5, 2026
Estimated time to complete activity: 60 minutes

PROVIDER STATEMENT

Provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

Supported by educational grants from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Sanofi.

PROGRAM OVERVIEW

The treatment of myeloma has changed dramatically over the last decade, including integration of a gentler approach and an emphasis on achieving deep and durable responses to primary therapy.

Today, anti-CD38 monoclonal antibody-based (mAb) quadruplet therapy is a standard of care .New data on quadruplet regimens offer more therapeutic options to patients. This clinical brief reviews recent results from the phase 3 PERSEUS and IsKia clinical trials of anti-CD38 mAb-based quadruplet therapy for patients with newly diagnosed myeloma who are eligible for transplant. The clinical relevance of these results will be discussed.

Learning Objective

TARGET AUDIENCE

This educational activity was designed for medical oncologists, hematologists, advance practice professionals and nurses who treat and manage patients with multiple myeloma.

LEARNING OBJECTIVE

Upon completion of this educational activity, participants should be able to:

Appraise the clinical implications of recent anti-CD38 antibody studies for patients with multiple myeloma

Faculty Information and Disclosures

FACULTY CHAIR

Saad Z. Usmani, MD, MBA, FACP 

Chief, Myeloma Service Memorial Sloan Kettering Cancer Center (MSK)

Member, Memorial Sloan Kettering Cancer Center

Attending Physician, Myeloma, Cellular Therapy and Adult BMT

Memorial Sloan Cancer Center

New York, New York

FACULTY DISCUSSANTS

Rahul Banerjee, MD, FACP

Assistant Professor, Clinical Research

Division Fred Hutchinson Cancer Center

Seattle, Washington

Surbhi Sidana, MD

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity CE, LLC requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity CE, LLC for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CME activity:

Rahul Banerjee, MD, FACP

Consultant: Adaptive, Bristol Myers Squibb, Caribou, Genentech, GlaxoSmithKline, Johnson and Johnson, Karyopharm Legend, Sanofi

Research: Abbvie, Bristol Myers Squibb, Johnson and Johnson, Novartis, Pack Health, Prothena, Sanofi

Surbhi Sidana, MD Saad Z. Usmani, MD, MBA, FACP, FRCP, FASCO

Consultant: AbbVie, Amgen, Bristol Myers Squibb, EdoPharma, Genentech, Gilead, GlaxoSmithKline, Janssen, Karyopharm Therapeutics, Merck, Oncopeptides, Sanofi, Seagen, Secura

Research: Amgen, Array Biopharma, Bristol Myers Squibb, EdoPharm

The Integrity CE, LLC planners and managers do not have any financial relationships or relationships to products or devices with ineligible companies.

Accreditation Information

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of October 30, 2024 through January 30, 2025, participants must:

Read the learning objectives
Complete the pretest
Study the educational activity
Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed posttest with a score of 100% and a completed activity evaluation form.

ACCREDITATION STATEMENT

Integrity CE, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity CE, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity CE, LLC at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity CE, LLC does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimers and Technical Requirements

MEDIA

Internet

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity CE, LLC, you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent) Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS Plug-in: Adobe^® Flash^® Player 10

Adobe^® Flash^® Player 10 plug-in should be downloaded
Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below: Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Release date: May 5, 2025Expiration date: May 5, 2026Estimated time to complete activity: 60 minutes

Magna in ut accusamu 9-9-25